You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. The first commercial rapid diagnostic test to detect Paragonimus infections

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Abstract We propose an ultrasensitive rapid diagnostic testRDTto detect exposure to pulmonary flukes of the genus ParagonimusParagonimiasis affects an estimatedmi l l ion people and remains amongst the most neglected of all neglected tropical diseasesNTDsThis trematode is acquired upon ingestion of raw or undercooked freshwater crustaceans and migrates to the lungs where it forms cystsTreatment is ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Biosensor and Eyedrop Bottle Technologies for Glaucoma Adherence Monitoring

    SBC: Toromedes, Inc            Topic: NEI

    Project SummaryNon adherence with prescribed systemic drugs leads to poor outcomes and increases the cost of healthcareGlaucomathe leading cause of irreversible blindnessaffects more thanmillion people worldwideLowering intraocular pressurethe only proven method of delaying both the development and progression of glaucomais typically done with topical administration of eye dropswhich has notorious ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury

    SBC: Mitovation, Inc.            Topic: 101

    Neonatal hypoxia ischemia is a known cause of cerebral damage resulting from inadequate blood flow and or oxygen delivery to the infant brain beforeduringor after birthThe occurrence among hospital deliveries isperfull term births with a drastic increase among premature newbornsThe deficit in oxygen delivery to the brain results in extensive damage and severe disabilitiesRestoration of blood flow ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. In Vivo Assessment of Embryonic Stem Cell Teratoma Prevention

    SBC: BIOINVISION INC            Topic: NICHD

    DESCRIPTION (provided by applicant): The capacity to evaluate the teratoma forming potential of differentiated embryonic stem cell populations represents an urgent need before widespread therapeutic application of these cells is possible. Researchers at Case Western Reserve University and BioInVision, Inc. will join together to create platform technologies for validating existing embryonic stem ce ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Live-Cell Fluorescence Lifetime FRET Assays for HTS

    SBC: Fluorescence Innovations, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Identification and Validation of Targets of Phenotypic High Throughput Screening

    SBC: COLLABORATIVE DRUG DISCOVERY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Identification and Validation of Targets of Phenotypic High Throughput Screening Hits for Chagas Disease Project Summary Nearly 10 million people in Latin America are infected with the eukaryotic parasite Trypanosoma cruzi, the causative agent of Chagas disease. The World Health Organization (WHO) classifies Chagas disease as a neglected tropical disease, but C ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS

    SBC: ZMK Medical Technologies, Inc.            Topic: 102

    ABSTRACTProstate cancerPCais one of the most commonly occurring forms of canceraccounting forof all cancer in menMulti parametric magnetic resonance imagingmpMRIhas led to improved capabilities for detectinglocalizingand staging PCaCombined with image guided prostate biopsympMRI has helped to improve diagnosis of clinically significant PCawhich helps to reduce mortality as well as unnecessary biop ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARY / ABSTRACT Every year, 50,000 very low birth weight (VLBW, andlt;1,500 g) infants are born in the U.S. The use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndrome (RDS) in VLBW infants. Current standards for surfactant administration require the infant to be intubated, so that surfactant can be delivered to the trachea and lungs. Intuba ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government